Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis

References

• Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(1):129–147.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536–538.
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–1542.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Carraway HE, Saygin C. Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020;2020(1):426–433.
   PubMedGoogle Scholar
• Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019;2019(1):381–390.
   PubMedGoogle Scholar
• de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753–1762.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189(6):1016–1027.
   PubMed Web of Science ®Google Scholar
• Garcia JS. Prospects for venetoclax in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2020;34(2):441–448.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• FDA.gov [Internet]. [cited 2020 Oct 16]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia.
   Google Scholar
• ascopost.com [Internet]. Huntington (NY): Harborside; [cited 2021 Jul 23]. Available from: https://ascopost.com/news/july-2021/fda-pipeline-designations-for-therapies-in-myelodysplastic-syndromes-and-triple-negative-breast-cancer/.
   Google Scholar
• National Institute of Health: National Heart, Lung, and Blood Institute [Internet]. Bethesda (MD): [cited Jul 2021]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
   Google Scholar
• Schwarzer G. General package for meta-analysis. R news. 2022. Available from: https://cran.r-project.org/web/packages/meta/meta.pdf.
   Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Ali NA, Sallman D, Chan O, et al. MDS-128: azacitidine and venetoclax combination for upfront treatment of higher-risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leukemia. 2021;21:S341.
   Web of Science ®Google Scholar
• Azizi A, Ediriwickrema A, Dutta R, et al. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leuk Lymphoma. 2020;61(11):2700–2707.
   PubMed Web of Science ®Google Scholar
• Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4(13):2866–2870.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Derkach A, Gowda L, et al. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021;62(14):3394–3401.
   PubMed Web of Science ®Google Scholar
• Cortes J, Garcia-Manero G, Sasaki K, et al. Activity of Venetoclax-Based therapy in myelodysplastic syndrome (MDS). Blood. 2019;134(Supplement_1):1726–1726.
   Google Scholar
• Desikan SPP, Montalban-Bravo G, Ohanian M, et al. A phase I study of the combination of venetoclax and azacitidine in relapse/refractory higher risk myelodysplastic syndrome (MDS). Blood. 2021;138(Supplement 1):3704–3704.
   Google Scholar
• Feld J, Tremblay D, Dougherty M, et al. Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed/refractory advanced myeloid malignancies. HemaSphere. 2021;5(4):e549.
   PubMed Web of Science ®Google Scholar
• Garcia JS, Wei AH, Jacoby MA, et al. Molecular responses are observed across mutational spectrum in Treatment-Naïve Higher-Risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. Blood. 2021;138(Supplement 1):241–241.
   Google Scholar
• Gemici A, Ozkalemkas F, Dogu MH, et al. A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(8):e686–e692.
   PubMed Web of Science ®Google Scholar
• Jädersten M, Boriskina K, Lindholm C, et al. Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation. Leuk Lymphoma. 2022;63(3):755–758.
   PubMed Web of Science ®Google Scholar
• Maiti A, Dinardo CD, Pemmaraju N, et al. Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS. JCO. 2020;38(15_suppl):7519–7519.
   Web of Science ®Google Scholar
• Mei C, Ye L, Ren Y, et al. Venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes and acute myeloid leukemia: a retrospective single-center study. HemaSphere. 2021;5(SUPPL 2):431.
   Google Scholar
• Pullarkat V, Pratz KW, Döhner H, et al. Venetoclax and azacitidine combination in chemotherapy ineligible patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Hemasphere. 2021;5(SUPPL 2):422–423.
   Google Scholar
• Shapiro LC, Mantzaris I, Shastri A, et al. Low-dose weekly decitabine and venetoclax in TP53-mutated myeloid malignancies. Blood. 2021;138(Supplement 1):4428–4428.
   Google Scholar
• Uchida E, Lei MM, Brunner AM, et al. Evaluating venetoclax treatment duration when combined with hypomethylating agents in patients with acute myeloid leukemia or myelodysplastic syndromes. Blood. 2021;138(Supplement 1):4412–4412.
   Google Scholar
• Zeidan AM, Borate U, Pollyea DA, et al. Venetoclax and azacitidine in the treatment of patients with relapsed/refractory myelodysplastic syndrome. Blood. 2021;138(Supplement 1):537–537.
   Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa J-PJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer. 2006;106(8):1794–1803.
   PubMed Web of Science ®Google Scholar
• Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018;8(5):180002.
   PubMed Web of Science ®Google Scholar
• Jilg S, Reidel V, Müller-Thomas C, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30(1):112–123.
   PubMed Web of Science ®Google Scholar
• Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96(12):3932–3938.
   PubMed Web of Science ®Google Scholar
• Jilg S, Kauschinger J, Reidel V, et al. Combination of 5-Azacytidine and ABT-199 has a synergistic apoptotic effect in high-risk MDS/sAML after HMA failure. Blood. 2016;128(22):4297–4297.
   Web of Science ®Google Scholar
• Jilg S, Hauch RT, Kauschinger J, et al. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. Exp Hematol Oncol. 2019;8:9.
   PubMed Web of Science ®Google Scholar
• Reidel V, Kauschinger J, Hauch RT, et al. Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. Oncotarget. 2018;9(25):17270–17281.
   PubMedGoogle Scholar
• Wei Y, Cao Y, Jin X, et al. Low-dose decitabine plus venetoclax maintenance therapy can decrease the relapse after allogeneic stem cell transplantation for MRD positive HIGH-RISK acute myeloid leukemia and myelodysplastic syndrome. Blood. 2020;136(Supplement 1):33–33.
   Google Scholar
• Wei AH, Garcia JS, Borate U, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplasic syndrome. Blood. 2019;134(Supplement_1):568–568.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83(4):846–854.
   PubMed Web of Science ®Google Scholar
• Liu B, Guo Y, Deng L, et al. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Hematology. 2020;25(1):414–423.
   PubMed Web of Science ®Google Scholar